Cassiopea S.p.A. | Ownership
Companies that own Cassiopea S.p.A.
AMG Fondsverwaltung AG
312,923
3.13%
24,920
2.34%
12/31/2017
UBS AG (Investment Management)
188,956
1.89%
-269
0.01%
09/04/2018
Bellevue Asset Management AG
56,061
0.56%
-13,563
0.05%
05/31/2018
EFG Asset Management (UK) Ltd.
50,000
0.5%
0
0.46%
04/30/2018
Credit Suisse Asset Management (Schweiz) AG
42,733
0.43%
231
0%
05/31/2018
T. Rowe Price International Ltd.
41,881
0.42%
7,380
0.01%
06/30/2018
Zürcher Kantonalbank (Investment Management)
29,781
0.3%
2,010
0.01%
07/31/2018
Pictet Asset Management SA
13,567
0.14%
0
0%
03/31/2018
Deka Investment GmbH
13,500
0.14%
9,000
0%
06/29/2018
Union Bancaire Privée, UBP SA
13,315
0.13%
7,570
0.05%
03/31/2018
| Address |
Via Cristoforo Colombo, 1
Milan Milan 20020
Italy
|
|
Employees
|
- |
| Website |
http://www.cassiopea.com |
| Updated |
07/08/2019 |
| Cassiopea SpA is a clinical-stage specialty pharmaceutical company. It engages in developing and commercializing and medical dermatology products focusing on the topical treatment of acne, androgenic alopecia, and genital warts. The company products include Winlevi, Breezula, CB-06-02 and CB-06-01. |
